What is new in cancer-associated fibroblast biomarkers?

被引：24
作者：
Zhao, Zehua [1 ]
Li, Tianming [1 ]
Yuan, Yuan [2 ,3 ,4 ]
Zhu, Yanmei [1 ]
机构：
[1] Dalian Univ Technol, China Med Univ, Liaoning Canc Hosp & Inst, Dept Pathol,Affiliated Canc Hosp,Canc Hosp, 44 Xiaoheyan Rd, Shenyang 110042, Peoples R China
[2] China Med Univ, Hosp 1, Tumor Etiol & Screening Dept, Canc Inst & Gen Surg, Shenyang, Peoples R China
[3] China Med Univ, Hosp 1, Liaoning Educ Dept, Key Lab Canc Etiol & Prevent, Shenyang, Peoples R China
[4] China Med Univ, Hosp 1, Key Lab GI Canc Etiol & Prevent Liaoning Prov, 155 Nanjing Rd, Shenyang 110001, Peoples R China
来源：
CELL COMMUNICATION AND SIGNALING | 2023年 / 21卷 / 01期
关键词：
Cancer-associated fibroblasts; Biomarker; Heterogeneity; Targeted therapy; CARCINOMA-ASSOCIATED FIBROBLASTS; SMOOTH MUSCLE ACTIN; PODOPLANIN-POSITIVE FIBROBLASTS; ENHANCER-BINDING PROTEIN-1; TO-MESENCHYMAL TRANSITION; HUMAN BREAST-CANCER; ACTIVATION PROTEIN; TUMOR MICROENVIRONMENT; STROMAL CELLS; TENASCIN-C;
D O I：
10.1186/s12964-023-01125-0
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The tumor microenvironment is one of the important drivers of tumor development. Cancer-associated fibroblasts (CAFs) are a major component of the tumor stroma and actively participate in tumor development, invasion, metastasis, drug resistance, and other biological behaviors. CAFs are a highly heterogeneous group of cells, a reflection of the diversity of their origin, biomarkers, and functions. The diversity of CAF origin determines the complexity of CAF biomarkers, and CAF subpopulations expressing different biomarkers may play contrasting roles in tumor progression. In this review, we provide an overview of these emerging CAF biomarkers and the biological functions that they suggest, which may give a better understanding of the relationship between CAFs and tumor cells and be of great significance for breakthroughs in precision targeted therapy for tumors.
引用
收藏
页数：23
相关论文
共 262 条
  • [1] PT-100, a small molecule dipeptidyl peptidase inhibitorg has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism
    Adams, S
    Miller, GT
    Jesson, MI
    Watanabe, T
    Jones, B
    Wallner, BP
    [J]. CANCER RESEARCH, 2004, 64 (15) : 5471 - 5480
  • [2] Agrawal D, 2002, J NATL CANCER I, V94, P513
  • [3] Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer
    Akella, Neha M.
    Ciraku, Lorela
    Reginato, Mauricio J.
    [J]. BMC BIOLOGY, 2019, 17 (1)
  • [4] Palladin isoforms 3 and 4 regulate cancer-associated fibroblast pro-tumor functions in pancreatic ductal adenocarcinoma
    Alexander, J., I
    Vendramini-Costa, D. B.
    Francescone, R.
    Luong, T.
    Franco-Barraza, J.
    Shah, N.
    Gardiner, J. C.
    Nicolas, E.
    Raghavan, K. S.
    Cukierman, E.
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [5] Fibroblast activation protein-alpha knockdown suppresses prostate cancer cell invasion and proliferation
    An, Jiali
    Hou, Dingkun
    Wang, Lei
    Wang, Lili
    Yang, Yuanyuan
    Wang, Haitao
    [J]. HISTOLOGY AND HISTOPATHOLOGY, 2022, 37 (06) : 597 - 607
  • [6] Elimination of NF-κB signaling in Vimentin plus stromal cells attenuates tumorigenesis in a mouse model of Barrett's Esophagus
    Anand, Akanksha
    Fang, Hsin-Yu
    Mohammad-Shahi, Donja
    Ingermann, Jonas
    Baumeister, Theresa
    Strangmann, Julia
    Schmid, Roland M.
    Wang, Timothy C.
    Quante, Michael
    [J]. CARCINOGENESIS, 2021, 42 (03) : 405 - 413
  • [7] Aronson KJ, 2000, CANCER EPIDEM BIOMAR, V9, P55
  • [8] Periostin regulates fibrocyte function to promote myofibroblast differentiation and lung fibrosis
    Ashley, S. L.
    Wilke, C. A.
    Kim, K. K.
    Moore, B. B.
    [J]. MUCOSAL IMMUNOLOGY, 2017, 10 (02) : 341 - 351
  • [9] Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway
    Bao, SD
    Ouyang, G
    Bai, XF
    Huang, Z
    Ma, CY
    Liu, M
    Shoo, R
    Anderson, RM
    Rich, JN
    Wang, XF
    [J]. CANCER CELL, 2004, 5 (04) : 329 - 339
  • [10] The rationale for targeting the LOX family in cancer
    Barker, Holly E.
    Cox, Thomas R.
    Erler, Janine T.
    [J]. NATURE REVIEWS CANCER, 2012, 12 (08) : 540 - 552
12345678910